Treatment with the immunoconjugate trastuzumab deruxtecan leads to unprecedented improvements in response and overall survival in patients with HER2-positive (HER2+) metastatic gastroesophageal carcinoma (GEA), according to a study published in the New England Journal of Medicine. Until now, no HER2-targeted drugs other than trastuzumab have shown significant benefit in patients with HER2+ GEA.

中文翻译：

---

突破HER2 +癌症的障碍。

根据发表在《新英格兰医学杂志》上的一项研究，用免疫缀合物曲妥珠单抗德鲁塞康治疗可导致HER2阳性（HER2 +）转移性胃食管癌（GEA）患者的反应和总体生存率空前提高。到目前为止，除曲妥珠单抗外，没有针对HER2的药物对HER2 + GEA患者显示出明显的益处。